Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak*, Ronald de Wit, Kim N. Chi, Alexandra Drakaki, Cora N. Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed Hussain, Aude Flechon, Aristotelis Bamias, Evan Y. Yu, Michiel S. van der Heijden, Nobuaki Matsubara, Boris Alekseev, Andrea Necchi, Lajos Geczi, Yen-Chuan Ou, Hasan Senol Coskun, Wen-Pin Su, Miriam HegemannIvor J. Percent, Jae-Lyun Lee, Marcello Tucci, Andrey Semenov, Fredrik Laestadius, Avivit Peer, Giampaolo Tortora, Sufia Safina, Xavier Garcia del Muro, Alejo Rodriguez-Vida, Irfan Cicin, Hakan Harputluoglu, Ryan C. Widau, Astra M. Liepa, Richard A. Walgren, Oday Hamid, Annamaria H. Zimmermann, Katherine M. Bell-McGuinn, RANGE Study Investigators, Maureen Aarts - Essers, Thomas Powles

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2266-2277
Number of pages12
JournalLancet
Volume390
Issue number10109
DOIs
Publication statusPublished - 18 Nov 2017

Keywords

  • TRANSITIONAL-CELL-CARCINOMA
  • ENDOTHELIAL GROWTH-FACTOR
  • BLADDER-CANCER
  • OPEN-LABEL
  • FACTOR RECEPTOR-2
  • 2ND-LINE THERAPY
  • BREAST-CANCER
  • LUNG-CANCER
  • FOLLOW-UP
  • II TRIAL

Cite this